Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $58.97
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 21, 26 | Citizens | maintain | Market Outperform | Market Outperform |
| Oct 12, 26 | BTIG | maintain | Buy | Buy |
| Oct 2, 26 | Freedom Capital Markets | downgrade | Buy | Hold |
| Sep 2, 26 | Needham | maintain | Buy | Buy |
| Aug 27, 26 | Piper Sandler | maintain | Overweight | Overweight |
| Aug 24, 26 | BTIG | maintain | Buy | Buy |
| Jul 28, 26 | UBS | maintain | Buy | Buy |
| May 6, 26 | Canaccord Genuity | maintain | Buy | Buy |
| Feb 18, 26 | Citizens | maintain | Market Outperform | Market Outperform |
TTM vs. 5-year historical average (annual ratios)
| Metric | ATRC | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 277.9x | -46.4x · sector 20.7x | Elevated |
| Forward P/E (FY26E) | 544.2x | EPS est. 0.11 | Elevated |
| Price / Book | 5.5x | 4.3x | Elevated |
| Price / Sales | 5.3x | 5.7x | In line |
| EV / EBITDA | 76.9x | -37.5x | Discount |
| Return on equity | 2.1% | — | Weak |
| Gross margin | 76.2% | 74.8% | In line |
| Debt / Equity | 0.14 | 0.16 | Conservative |
| Piotroski / Altman Z | 8/9 | Z 11.79 | Safe zone |
Discounted cash flow model
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 60.53 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 89.46 | Oscillator | Sell |
| Williams %R (14) | -7.44 | Oscillator | Sell |
| MACD (12, 26, 9) | 1.19 (Hist 0.05) | Oscillator | Strong Buy |
| Average Directional Index (14) | 29.10 (+DI 26.8 / -DI 14.7) | Trend | Strong Buy |
| EMA 20 | 56.69 | MA | Strong Buy |
| SMA 20 | 56.39 | MA | Strong Buy |
| EMA 50 | 52.90 | MA | Strong Buy |
| SMA 50 | 54.03 | MA | Strong Buy |
| SMA 200 | 37.52 | MA | Strong Buy |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
Stock news · updated daily
Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE: TSM). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Taiwan Semiconductor Manufacturing stock on September 22nd. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2026 financial results on Tuesday, November 3, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, November 3, 2026, to discuss its third quarter financial results. Those interested in liste.
AtriCure, Inc. (NASDAQ: ATRC - Get Free Report) shares reached a new 52-week high during trading on Wednesday. The company traded as high as $60.99 and last traded at $60.9210, with a volume of 76652 shares traded. The stock had previously closed at $58.83. Wall Street Analysts Forecast Growth Several brokerages have recently weighed in on
Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
The transaction was valued at $201,000. The sale represented 2% of the insider's direct equity holdings prior to the transaction.
Investors need to pay close attention to ATRC stock based on the movements in the options market lately.
AtriCure (ATRC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 23, 2026 | -0.00 | 0.18 | Beat 10878.4% | $153.6M |
| May 5, 2026 | -0.07 | 0.00 | Beat 103.1% | $141.2M |
| Feb 17, 2026 | -0.04 | 0.06 | Beat 249.9% | $140.5M |
| Oct 29, 2025 | -0.11 | -0.01 | Beat 90.9% | $134.3M |
| Jul 29, 2025 | -0.15 | -0.13 | Beat 13.3% | $136.1M |
| Apr 29, 2025 | -0.25 | -0.14 | Beat 44.0% | $123.6M |
| 4 | Sep 4, 2026 | 2026-09-04 07:39:29 | View |
| 4 | Aug 26, 2026 | 2026-08-26 06:50:10 | View |
| SC 13G/A | Aug 14, 2026 | 2026-08-14 15:30:40 | View |
| 4 | Aug 7, 2026 | 2026-08-07 09:18:41 | View |
| 4 | Aug 7, 2026 | 2026-08-07 09:18:33 | View |
| 4 | Aug 3, 2026 | 2026-08-03 07:18:20 | View |
Proxy statement (DEF 14A) disclosures
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 23, 26 | Privitera Salvatore | officer: Chief Technical Officer | S-Sale | 4,519 @ $60.00 | $271.1K |
| Sep 11, 26 | Groves Regina E | director | S-Sale | 5,313 @ $54.22 | $288.1K |
| Sep 8, 26 | Privitera Salvatore | officer: Chief Technical Officer | S-Sale | 3,657 @ $55.00 | $201.1K |
| Sep 2, 26 | Privitera Salvatore | officer: Chief Technical Officer | S-Sale | 7,763 @ $52.50 | $407.6K |
| Aug 24, 26 | Dahlquist Karl S. | officer: Chief Legal Officer | S-Sale | 9,370 @ $48.89 | $458.1K |
| Aug 5, 26 | Prange Karen | director | S-Sale | 3,564 @ $38.80 | $138.3K |
| Aug 5, 26 | Yuen Maggie | director | S-Sale | 3,500 @ $38.42 | $134.5K |
| Jul 30, 26 | Carrel Michael H | director, officer: President, CEO, & Director | G-Gift | 700 | — |